SLCO1B3 and prostate neoplasm: Using prostate tumors as an example, it appears that OATP1B3 is overexpressed during disease development in the primary tumor, facilitates the survival of metastatic prostate lesions during androgen deprivation therapy [1], [5], [19], and may be involved in the sensitivity of CRPC tumors towards docetaxel due to increased uptake.